SMAC-armed vaccinia virus induces both apoptosis and necroptosis and synergizes the efficiency of vinblastine in HCC

Human Cell

Volumn 27, Issue 4, 2014, Pages 162-171

  Pan, Qiang ^a   Huang, Yuanyong ^b   Chen, Lieyang ^c   Gu, JinFa ^c   Zhou, Xiumei ^a  

^a ZHEJIANG SCI TECH UNIVERSITY   (China)

^b EAST CHINA NORMAL UNIVERSITY   (China)

^c INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

Apoptosis; Necroptosis; Ripoptosome; SMAC DIABLO; Vaccinia virus; Vinblastine

Indexed keywords

ANTINEOPLASTIC AGENT; DIABLO PROTEIN, HUMAN; MITOCHONDRIAL PROTEIN; SIGNAL PEPTIDE; THYMIDINE KINASE; VINBLASTINE;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; DRUG EFFECTS; DRUG POTENTIATION; ENZYMOLOGY; GENETICS; HUMAN; LIVER NEOPLASMS; NECROSIS; PATHOLOGY; TUMOR CELL LINE; VACCINIA VIRUS; VIROLOGY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DRUG SYNERGISM; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MITOCHONDRIAL PROTEINS; NECROSIS; THYMIDINE KINASE; VACCINIA VIRUS; VINBLASTINE;

EID: 84925883434     PISSN: 09147470     EISSN: 17490774     Source Type: Journal    
DOI: 10.1007/s13577-014-0093-z     Document Type: Article

References (34)

1. Bosch F, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127:S5–16.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2012;63:11–30.
3. Vadhan-Raj S. Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents. Semin Hematol. 2009;46:32.
4. Rodgers G 3rd, Becker P, Bennett C, et al. Cancer-and chemotherapy-induced anemia. J Natl Compr Cancer Netw JNCCN. 2008;6:536.
5. Wein L, Wu J, Kirn D. Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer Res. 2003;63:1317–24.
6. Vanderplasschen A, Mathew E, Hollinshead M, Sim R, Smith G. Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. Proc Natl Acad Sci USA. 1998;95:7544–9.
7. Thorne S, Hwang T-H, O’Gorman W, et al. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Investig. 2007;117:3350–8.
8. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.
9. Pankiv S, Clausen T, Lamark T, et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem. 2007;282:24131–45.
10. Hanahan D, Weinberg R. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
11. Shi Y-H, Ding W-X, Zhou J, et al. Expression of X-linked inhibitor-of-apoptosis protein in hepatocellular carcinoma promotes metastasis and tumor recurrence. Hepatology (Baltimore, Md). 2008;48:497–507.
12. Deveraux Q, Reed J. IAP family proteins—suppressors of apoptosis. Genes Dev. 1999;13:239–52.
13. Miller L. An exegesis of IAPs: salvation and surprises from BIR motifs. Trends Cell Biol. 1999;9:323–8.
14. Martinez-Ruiz G, Maldonado V, Ceballos-Cancino G, Grajeda J, Melendez-Zajgla J. Role of Smac/DIABLO in cancer progression. J Exp Clin Cancer Res CR. 2008;27:48.
15. Chai J, Du C, Wu J, Kyin S, Wang X, Shi Y. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature. 2000;406:855–62.
16. Yang Q-H, Du C. Smac/DIABLO selectively reduces the levels of c-IAP1 and c-IAP2 but not that of XIAP and livin in HeLa cells. J Biol Chem. 2004;279:16963–70.
17. Adrain C, Creagh E, Martin S. Apoptosis-associated release of Smac/DIABLO from mitochondria requires active caspases and is blocked by Bcl-2. EMBO J. 2001;20:6627–36.
18. Zhang Y, Gu J, Zhao L, et al. Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy. Cancer Res. 2006;66:4291–8.
19. Fulda S, Wick W, Weller M, Debatin K-M. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med. 2002;8:808–15.
20. Xu Y, Zhou L, Huang J, et al. Role of Smac in determining the chemotherapeutic response of esophageal squamous cell carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17:5412–22.
21. Scheiflinger F, Falkner FG, Dorner F. Evaluation of the thymidine kinase (tk) locus as an insertion site in the highly attenuated vaccinia MVA strain. Arch Virol. 1996;141:663–9.
22. Degterev A, Hitomi J, Germscheid M, et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol. 2008;4:313–21.
23. Cho Y, Challa S, Moquin D, et al. Phosphorylation-driven assembly of the RIP1–RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell. 2009;137:1112–23.
24. Vitale M, Zamai L, Mazzotti G, Cataldi A, Falcieri E. Differential kinetics of propidium iodide uptake in apoptotic and necrotic thymocytes. Histochemistry. 1993;100:223–9.
25. Huang H, Xiao T, He L, Ji H, Liu X-Y. Interferon-β-armed oncolytic adenovirus induces both apoptosis and necroptosis in cancer cells. Acta Biochim Biophys Sin. 2012;44:737–45.
26. Kroemer G, Martin SJ. Caspase-independent cell death. Nat Med. 2005;11:725–30.
27. Bertrand Mathieu JM, Vandenabeele P. The ripoptosome: death decision in the cytosol. Mol Cell. 2011;43:323–5.
28. Tenev T, Bianchi K, Darding M, et al. The ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell. 2011;43:432–48.
29. Pan QW, Zhong SY, Liu BS, et al. Enhanced sensitivity of hepatocellular carcinoma cells to chemotherapy with a Smac-armed oncolytic adenovirus. Acta Pharmacol Sin. 2007;28:1996–2004.
30. Jordan M, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:253–65.
31. Kirn D, Thorne S. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer. 2009;9:64–71.
32. Breitbach C, Burke J, Jonker D, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature. 2011;477:99–102.
33. Waibler Z, Anzaghe M, Frenz T, et al. Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components. J Virol. 2009;83:1563–71.
34. Wu S, Zheng SD, Huang HL, et al. Lithium downregulates HDAC1 and induces degradation of mutant huntingtin. J Biol Chem. 2013;288:35500–10.